| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1012250533 |
| P356 | DOI | 10.2165/00002018-200124100-00004 |
| P698 | PubMed publication ID | 11676303 |
| P2093 | author name string | R Moore | |
| D Hernandez | |||
| H Valantine | |||
| P2860 | cites work | Efficacy and muscle safety of fluvastatin in cyclosporine-treated cardiac and renal transplant recipients: an exercise provocation test | Q77590781 |
| Meta-Analysis of the Effects of Soy Protein Intake on Serum Lipids | Q28292288 | ||
| Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group | Q28374428 | ||
| A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients | Q28375945 | ||
| Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study | Q29617822 | ||
| Hyperlipidemia in patients with chronic renal disease | Q77573739 | ||
| Diet, cholesterol and coronary heart disease. A perspective. | Q33729252 | ||
| Mechanisms of chronic rejection | Q33781406 | ||
| The effects of lipids on graft outcome | Q33781416 | ||
| Cardiovascular disease after renal transplantation | Q33881037 | ||
| Kidney transplantation from living unrelated donors | Q33896083 | ||
| Comparative tolerability of the HMG-CoA reductase inhibitors | Q34045770 | ||
| Evolution and etiology of cardiovascular diseases in renal transplant recipients | Q34127597 | ||
| Impact and management of hyperlipidemia posttransplantation | Q34127609 | ||
| Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) | Q34467101 | ||
| Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial | Q34663253 | ||
| Prominence of coronary arterial wall lipids in human heart allografts. Implications for pathogenesis of allograft arteriopathy | Q35796013 | ||
| Immune-deficient mice develop typical atherosclerotic fatty streaks when fed an atherogenic diet | Q35824745 | ||
| Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. | Q36053814 | ||
| Post-transplant hyperlipidaemia | Q36728201 | ||
| Posttransplant hyperlipidemia: the treatment dilemma | Q40747345 | ||
| Risk factors for cardiovascular disease after renal transplantation. | Q40776231 | ||
| Cardiovascular risk factors and diseases after renal transplantation | Q40818233 | ||
| Approaches to the treatment of hyperlipidemia in the solid organ transplant recipient | Q40938703 | ||
| Lipid-lowering therapy in patients with renal disease | Q40981407 | ||
| Hyperlipidemia After Renal Transplantation: Natural History and Pathophysiology | Q41103475 | ||
| A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group | Q41439111 | ||
| Posttransplant medical complications | Q41734045 | ||
| Effect of cyclosporin on plasma lipoproteins in bone marrow transplantation patients | Q41940288 | ||
| Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients. | Q42196011 | ||
| Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin | Q42664250 | ||
| Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia | Q43440566 | ||
| Impact of long-term immunosuppression with cyclosporin A on serum lipids in stable renal transplant recipients | Q43573422 | ||
| Lipoprotein and hepatic lipase activity and high-density lipoprotein subclasses after cardiac transplantation | Q43643720 | ||
| The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients | Q44240318 | ||
| Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study | Q45109356 | ||
| Lipid abnormalities in black renal patients. | Q46168381 | ||
| Effect of pravastatin on outcomes after cardiac transplantation. | Q46203599 | ||
| Therapy of hyperlipidemia with lovastatin in kidney transplant patients on cyclosporine A immunosuppression: three-year experience | Q47940010 | ||
| Effects of cyclosporin A and FK 506 on lipid metabolism and fibrinogen in kidney transplant recipients. | Q50950422 | ||
| Hyperlipidaemia in renal transplant patients. | Q51031645 | ||
| Short-term effect of atorvastatin in hypercholesterolaemic renal-transplant patients unresponsive to other statins. | Q51553852 | ||
| Serum cholesterol changes in long-term survivors of liver transplantation: a comparison between cyclosporine and tacrolimus therapy. | Q51563839 | ||
| Metabolic liver function and lipoprotein metabolism after orthotopic liver transplantation in patients on immunosuppressive therapy with FK 506 or cyclosporine. | Q51612615 | ||
| The effect of FK506 versus cyclosporine on glucose and lipid metabolism--a randomized trial | Q53015764 | ||
| Changed composition of high-density lipoprotein subclasses HDL2 and HDL3 after renal transplantation. | Q53041509 | ||
| Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. | Q53546899 | ||
| Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. | Q53961304 | ||
| Role of statins in the management of dyslipidemia after cardiac transplant: randomized controlled trial comparing the efficacy and the safety of atorvastatin with pravastatin | Q57009979 | ||
| Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression | Q57377991 | ||
| Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study | Q57943257 | ||
| Lipid Disorders in Renal Transplant Recipients | Q66887070 | ||
| Lovastatin treatment of hypercholesterolemia in renal transplant recipients | Q67269991 | ||
| The effects of pravastatin on hyperlipidemia in renal transplant recipients | Q67735533 | ||
| Hyperlipidemia in Stable Renal Transplant Recipients | Q67796057 | ||
| Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations | Q68096185 | ||
| Risk factors for accelerated atherosclerosis in renal transplant recipients | Q68142393 | ||
| Persistent hyperlipidemia in renal transplant patients | Q68163915 | ||
| The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells | Q69735186 | ||
| Adverse effect of cyclosporin on plasma cholesterol in renal transplant recipients | Q70406468 | ||
| Dyslipidemia in renal transplantation: a 3-year follow-up | Q70775096 | ||
| Kidney-pancreas transplantation. The effect of portal versus systemic venous drainage of the pancreas on the lipoprotein composition | Q70855434 | ||
| Impact of serum lipids on long-term graft and patient survival after renal transplantation | Q70855447 | ||
| Metabolic problems in recipients of liver transplants | Q71146116 | ||
| Role of lipids in allograft vascular disease: a multicenter study of intimal thickening detected by intravascular ultrasound | Q71289633 | ||
| Cardiovascular disease after renal transplantation | Q71534443 | ||
| Increased low density lipoprotein oxidation in stable kidney transplant recipients | Q71568706 | ||
| Serum lipid changes in liver transplant recipients in a prospective trial of cyclosporine versus FK506 | Q71623641 | ||
| Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients | Q71653197 | ||
| Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine A US Multicenter Trial. US Multicenter Study Group | Q71677925 | ||
| Influence of long-term cyclosporine or FK 506 therapy on glucose and lipid metabolism in stable liver graft recipients | Q71677947 | ||
| Hyperlipidaemia in renal transplantation—risk factor for long‐term graft outcome | Q71814896 | ||
| Effect of fluvastatin for safely loweringatherogenic lipids in renal transplant patients receiving cyclosporine | Q71857063 | ||
| Effect of pravastatin in the treatment of hypercholesterolemia after renal transplantation under cyclosporine and prednisone | Q72003544 | ||
| The role of lipoprotein abnormalities in chronic vascular rejection after kidney transplantation | Q72339242 | ||
| Risk factors predicting chronic rejection of renal allografts | Q72730728 | ||
| Serum lipoproteins in renal transplant patients: the effect of cyclosporine on lipoprotein(a) | Q72755242 | ||
| Effect of dietary fish oil on renal function and rejection in cyclosporine-treated recipients of renal transplants | Q72878322 | ||
| Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study | Q73106332 | ||
| Prospective study of lipid disorders in FK506-versus cyclosporine-treated renal transplant patients | Q73544598 | ||
| Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation | Q73648786 | ||
| Are lipid-dependent indicators of cardiovascular risk affected by renal transplantation? | Q73688002 | ||
| Hyperlipidaemia and post-heparin lipase activities in renal transplant recipients treated with sirolimus or cyclosporin A | Q73834823 | ||
| Cholesterol as an independent predictor of outcome after renal transplantation | Q73847374 | ||
| Immunization with homologous oxidized low density lipoprotein reduces neointimal formation after balloon injury in hypercholesterolemic rabbits | Q73914311 | ||
| Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection | Q74191545 | ||
| Explained and unexplained ischemic heart disease risk after renal transplantation | Q74246088 | ||
| Genetic variations of the apolipoprotein E gene determine the plasma triglyceride levels after heart transplantation | Q74248771 | ||
| Steroid withdrawal is safe and beneficial in stable cyclosporine-treated liver transplant patients | Q74429552 | ||
| Lipid abnormalities in stable liver transplant recipients--effects of cyclosporin, tacrolimus, and steroids | Q74484777 | ||
| Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS) | Q74519754 | ||
| Serum lipid changes in liver transplantation: effect of steroids withdrawn in a prospective randomized trial under cyclosporine A therapy | Q74616188 | ||
| Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation: long-term results | Q74686020 | ||
| Cardiovascular morbidity and risk factors in renal transplant patients | Q77292190 | ||
| The importance of obesity and hyperlipidaemia in patients with renal transplants | Q77297535 | ||
| Drugs causing dyslipoproteinemia | Q77452765 | ||
| [Influence of genetic variation at apoprotein A-1 gene promoter region on plasma lipid levels in heart transplantation patients] | Q77537786 | ||
| P433 | issue | 10 | |
| P921 | main subject | hyperlipidemia | Q1079120 |
| P304 | page(s) | 755-766 | |
| P577 | publication date | 2001-01-01 | |
| P1433 | published in | Drug Safety | Q15724462 |
| P1476 | title | Calcineurin inhibitors and post-transplant hyperlipidaemias | |
| P478 | volume | 24 |
| Q79564141 | Beneficial effect of DL-alpha-lipoic acid on cyclosporine A induced hyperlipidemic nephropathy in rats |
| Q35586587 | Calreticulin is an upstream regulator of calcineurin |
| Q44577572 | Cardiovascular risk profile in nondiabetic renal transplant patients: cyclosporine versus tacrolimus |
| Q45069261 | Conversion from cyclosporine A to mycophenolate mofetil protects recipient kidney and prevents intimal hyperplasia in rat aortic allografts |
| Q74069835 | Current awareness in pharmacoepidemiology and drug safety |
| Q37226086 | Does African American Race Impact Statin Efficacy in Renal Transplant Outcomes? |
| Q35710914 | Experience with cyclosporine in the Canary Islands |
| Q36163801 | Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation |
| Q57750555 | Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients |
| Q38240865 | Immunosuppression in lung transplantation |
| Q55547403 | New frontiers in immunosuppression. |
| Q45248050 | Role of apolipoprotein E epsilon 4 allele on chronic allograft nephropathy after renal transplantation. |
| Q46045883 | Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin with rapamycin plus tacrolimus in liver transplant patient. |
| Q45068928 | Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: randomised European multicentre trial |
| Q24202759 | Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients |
| Q24236783 | Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients |
| Q30318847 | The novel calcineurin inhibitor CN585 has potent immunosuppressive properties in stimulated human T cells. |
Search more.